Webdisclosure.com

SANOFI-AVENTIS (EPA:SAN)

25/06/2021 07:30

Sanofi: Availability of the Q2 2021 Memorandum for modelling purposes

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

18/06/2021 15:45

European Commission approves Aubagio® (teriflunomide) as the first oral MS therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

11/06/2021 09:00

New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with CAD, a serious and chronic autoimmune hemolytic anemia

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

04/06/2021 07:00

Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

03/06/2021 14:00

Sanofi launches €3 million Planet Mobilization fund to support employees’ environmental projects

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

19/05/2021 23:45

Sanofi to showcase data from its transformative oncology pipeline at 2021 ASCO Meeting

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

19/05/2021 23:00

Early amcenestrant data featured at ASCO support its potential to become a new endocrine backbone therapy for ER+/HER2- breast cancer

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

17/05/2021 16:00

Pivotal data at ATS 2021 show Dupixent® (dupilumab) significantly reduced asthma attacks and improved lung function in children

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

26/04/2021 08:00

Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

23/04/2021 16:05

New Dupixent® (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years

Voir tous les communiqués de SANOFI-AVENTIS

«
4
5
6
7
8
9
10